Bavarian Nordic A/S (BVNRY)
USD 9.23
(-0.22%)
USD 9.23
(-0.22%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.52 Billion DKK | 165.79% |
| 2022 | 1.7 Billion DKK | 198.3% |
| 2021 | 570.31 Million DKK | -13.23% |
| 2020 | 657.28 Million DKK | 113.59% |
| 2019 | 307.73 Million DKK | 25.35% |
| 2018 | 245.5 Million DKK | -77.26% |
| 2017 | 1.07 Billion DKK | 52.27% |
| 2016 | 708.94 Million DKK | 17.1% |
| 2015 | 605.42 Million DKK | -16.12% |
| 2014 | 721.73 Million DKK | -0.83% |
| 2013 | 727.79 Million DKK | 44.67% |
| 2012 | 503.08 Million DKK | 318.49% |
| 2011 | 120.21 Million DKK | 192.19% |
| 2010 | -130.39 Million DKK | -99.64% |
| 2009 | -65.31 Million DKK | -637.79% |
| 2008 | 12.14 Million DKK | -95.62% |
| 2007 | 276.98 Million DKK | 329.47% |
| 2006 | 64.49 Million DKK | -44.1% |
| 2005 | 115.37 Million DKK | 22.04% |
| 2004 | 94.53 Million DKK | -70.22% |
| 2003 | 317.45 Million DKK | 391.24% |
| 2002 | 64.62 Million DKK | 0.0% |
| 2001 | - DKK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 719.95 Million DKK | 171.44% |
| 2024 Q1 | 265.23 Million DKK | -83.59% |
| 2023 FY | 4.52 Billion DKK | 165.79% |
| 2023 Q4 | 1.61 Billion DKK | 87.54% |
| 2023 Q1 | 823.65 Million DKK | -13.13% |
| 2023 Q3 | 862.03 Million DKK | -33.84% |
| 2023 Q2 | 1.3 Billion DKK | 58.18% |
| 2022 Q3 | 619.81 Million DKK | 488.14% |
| 2022 Q4 | 948.19 Million DKK | 52.98% |
| 2022 Q1 | 27.87 Million DKK | -82.24% |
| 2022 Q2 | 105.38 Million DKK | 278.09% |
| 2022 FY | 1.7 Billion DKK | 198.3% |
| 2021 Q1 | 157.91 Million DKK | 261.11% |
| 2021 Q3 | 134.74 Million DKK | 11.64% |
| 2021 FY | 570.31 Million DKK | -13.23% |
| 2021 Q4 | 156.96 Million DKK | 16.49% |
| 2021 Q2 | 120.69 Million DKK | -23.57% |
| 2020 Q2 | 320.08 Million DKK | 161.68% |
| 2020 Q1 | 122.32 Million DKK | -21.36% |
| 2020 Q4 | -98.01 Million DKK | -131.32% |
| 2020 FY | 657.28 Million DKK | 113.59% |
| 2020 Q3 | 312.89 Million DKK | -2.25% |
| 2019 Q4 | 155.55 Million DKK | 202.94% |
| 2019 Q1 | 49.27 Million DKK | -30.97% |
| 2019 Q2 | 51.55 Million DKK | 4.62% |
| 2019 FY | 307.73 Million DKK | 25.35% |
| 2019 Q3 | 51.34 Million DKK | -0.4% |
| 2018 Q2 | 40.68 Million DKK | 620.8% |
| 2018 Q4 | 71.38 Million DKK | -49.46% |
| 2018 Q1 | -7.81 Million DKK | -129.78% |
| 2018 FY | 245.5 Million DKK | -77.26% |
| 2018 Q3 | 141.24 Million DKK | 247.16% |
| 2017 Q3 | 635.53 Million DKK | 135.21% |
| 2017 Q4 | 26.23 Million DKK | -95.87% |
| 2017 FY | 1.07 Billion DKK | 52.27% |
| 2017 Q1 | 147.56 Million DKK | -52.38% |
| 2017 Q2 | 270.2 Million DKK | 83.11% |
| 2016 Q1 | 3.66 Million DKK | -97.53% |
| 2016 Q2 | 88.24 Million DKK | 2310.46% |
| 2016 FY | 708.94 Million DKK | 17.1% |
| 2016 Q3 | 307.2 Million DKK | 248.11% |
| 2016 Q4 | 309.84 Million DKK | 0.86% |
| 2015 FY | 605.42 Million DKK | -16.12% |
| 2015 Q4 | 148.08 Million DKK | 316.46% |
| 2015 Q3 | 35.55 Million DKK | -87.26% |
| 2015 Q2 | 279.1 Million DKK | 95.59% |
| 2015 Q1 | 142.7 Million DKK | -61.87% |
| 2014 Q3 | 126.1 Million DKK | 57.82% |
| 2014 Q4 | 374.23 Million DKK | 196.78% |
| 2014 FY | 721.73 Million DKK | -0.83% |
| 2014 Q1 | 141.5 Million DKK | -29.11% |
| 2014 Q2 | 79.9 Million DKK | -43.53% |
| 2013 Q2 | 269.9 Million DKK | 262.28% |
| 2013 Q3 | 183.8 Million DKK | -31.9% |
| 2013 Q4 | 199.59 Million DKK | 8.59% |
| 2013 FY | 727.79 Million DKK | 44.67% |
| 2013 Q1 | 74.5 Million DKK | -43.72% |
| 2012 Q3 | 158.7 Million DKK | 17.12% |
| 2012 Q2 | 135.5 Million DKK | 77.12% |
| 2012 Q4 | 132.38 Million DKK | -16.58% |
| 2012 FY | 503.08 Million DKK | 318.49% |
| 2012 Q1 | 76.5 Million DKK | -51.98% |
| 2011 Q4 | 159.31 Million DKK | 601.82% |
| 2011 Q3 | 22.7 Million DKK | 163.76% |
| 2011 FY | 120.21 Million DKK | 192.19% |
| 2011 Q2 | -35.6 Million DKK | -35.88% |
| 2011 Q1 | -26.2 Million DKK | -354.27% |
| 2010 Q3 | -103.9 Million DKK | -911.72% |
| 2010 FY | -130.39 Million DKK | -99.64% |
| 2010 Q4 | 10.3 Million DKK | 109.92% |
| 2010 Q2 | 12.8 Million DKK | 125.81% |
| 2010 Q1 | -49.6 Million DKK | -800.07% |
| 2009 Q3 | -8.9 Million DKK | 77.53% |
| 2009 Q4 | 7.08 Million DKK | 179.61% |
| 2009 FY | -65.31 Million DKK | -637.79% |
| 2009 Q2 | -39.6 Million DKK | -65.69% |
| 2009 Q1 | -23.9 Million DKK | 0.0% |
| 2008 FY | 12.14 Million DKK | -95.62% |
| 2007 FY | 276.98 Million DKK | 329.47% |
| 2006 FY | 64.49 Million DKK | -44.1% |
| 2005 FY | 115.37 Million DKK | 22.04% |
| 2004 FY | 94.53 Million DKK | -70.22% |
| 2003 FY | 317.45 Million DKK | 391.24% |
| 2002 FY | 64.62 Million DKK | 0.0% |
| 2001 FY | - DKK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -30080.472% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -145930557.64% |
| SQZ Biotechnologies Company | 9.79 Million USD | -46119.818% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -38570.502% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -3700.572% |
| Mesoblast Limited | -35.16 Million USD | 12971.841% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 13255646.12% |
| Genus plc | 178.7 Million USD | -2433.167% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -1103545.85% |
| Marizyme, Inc. | 457.7 Thousand USD | -988921.022% |
| ContraFect Corporation | -154 Thousand USD | 2939560.39% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 41152545.455% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 9053638.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -5897125.153% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -6887024.209% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 1168295.437% |
| MultiCell Technologies, Inc. | 49.32 USD | -9178363646.959% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -11142.441% |
| EV Biologics, Inc. | 48.9 Thousand USD | -9257096.319% |
| Q BioMed Inc. | -8988.00 USD | 50364686.115% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -15921.125% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 29348965.405% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | -1956.65% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -6466712.857% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 3643345.527% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -7274622.785% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 91413044.265% |
| Arch Therapeutics, Inc. | -2439.00 USD | 185599484.994% |
| IMV Inc. | -962.29 Thousand USD | 470512.388% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -3221799.644% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 4642225.827% |
| GB Sciences, Inc. | -624.00 USD | 725443850.0% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 5262071.684% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 40.13% |
| Halberd Corporation | -208.00 USD | 2176331350.0% |
| Enzolytics Inc. | 30.7 Thousand USD | -14741234.506% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -333451.365% |
| SYBLEU INC | 11.69 Thousand USD | -38703465.321% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -938220.762% |
| argenx SE | 1.1 Billion USD | -308.376% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 17646.977% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -733117.738% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | -1005.295% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 51115377.778% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -10105.122% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 396638.195% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -458083.811% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -46999.875% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 5398815.548% |
| BioStem Technologies, Inc. | 15.42 Million USD | -29247.254% |
| ONE Bio Corp. | 20.12 Million USD | -22392.769% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 38249098.733% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 9380254.997% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -2563770.072% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -2563770.072% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 879921.383% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 718477.403% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 15609648.276% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -1005752.552% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 1416898.067% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -98137.174% |
| Bioxytran, Inc. | -8285.00 USD | 54638229.149% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 1213710.992% |
| Neutra Corp. | 14.33 Thousand USD | -31578337.391% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 5520550.0% |
| PureTech Health plc | -1.6 Million USD | 282493.575% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 452218.082% |
| IXICO plc | 3.27 Million USD | -138333.303% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 652372.19% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 252850.921% |
| CSL Limited | 7.7 Billion USD | 41.249% |
| Cellectis S.A. | 18 Thousand USD | -25148616.667% |